Boosting its oncology pipeline, global pharma giant Johnson & Johnson has announced that it has finalized its $3.05 billion cash acquisition of Halda Therapeutics OpCo, Inc, a clinical-stage biotech company specializing in targeted oral therapies for cancers.
Halda’s proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform is designed to create precision therapies that can overcome treatment resistance.
“This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson.
“We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer.”
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease.
HLD-0915 leverages the RIPTAC platform to selectively target cancer cells, and the deal also brings early-stage candidates for breast, lung, and other tumors into the company’s growing oncology portfolio. The technology could extend beyond cancer, offering potential for transformative therapies in additional disease areas.
“Johnson & Johnson continuously seeks new ways to meet patient needs and deliver innovative therapies,” said John C Reed, Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson.
“Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond.”
,_Thyrocare.jpg)
